Sleep Apnoea Guidelines

The Pharmaceutical Society of Australia has launched new guidelines which aim to promote the standardisation of sleep apnoea services within pharmacies.  PSA National President Joe Demarte said the guidelines promote “policies and protocols designed to ensure effective channels of communication and collaboration between healthcare providers,” in line with the PSA’s ongoing recognition of the importance of continuity of care. 

The Practice guidelines for the provision of sleep apnoea services within pharmacy have been developed in collaboration with the Australasian Sleep Association, under a memorandum of understanding with the PSA.
Demarte said moderate-to-severe sleep apnoea, if left untreated, could lead to a range of health problems including hypertension, cardiovascular disease, stroke, diabetes and depression. The condition is also a safety risk for many people including longdistance drivers, he said.

Source:pharmacydaily.com.au, Monday 3 August 2015